Navigation Links
Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Date:11/16/2011

that its hemophilia B program was granted Orphan designation in the European Union.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 60 are not donor candidates for bone marrow transplantation. ... the elderly prone to life-threatening infection and other maladies, ... discovered a reason why. , "We have found the ... to maintain blood production over time in an old ... restored for rejuvenation therapies," said Emmanuelle Passegu, PhD, a ...
(Date:7/31/2014)... Chemists at Indiana University Bloomington have described the ... a development with potential value for the field ... and photovoltaic cells. , Their paper, "Anion-Induced Dimerization ... and 2D Self-Assembled Crystals," has been published online ... the Royal Society of Chemistry. It is the ...
(Date:7/31/2014)... Graphite Metallizing Corporation announces GRAPHALLOY® ... bearings are uniquely suited to prevent loss of lubrication ... the high temperatures . , Recently, a manufacturer ... engineers at Graphite Metallizing to overcome problems with movement ... operation, pans containing blocks of powder mixture are loaded ...
(Date:7/31/2014)... 2014 CollabRx, Inc. (NASDAQ: CLRX), a ... in oncology, today announced that it will hold an ... the Company's financial results for the first quarter of ... business in the current fiscal year. , The dial-in ... August 14, 2014, at 5 p.m. EDT (2 p.m. ...
Breaking Biology Technology:Key to aging immune system is discovered 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... Shandong, China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, ... the,"Company"), one of the leading plasma-based pharmaceutical companies ... that one of its R&D,projects, "High-Purity Human Albumin," ... China. , The National ...
... Prize, Draper Laboratory, in conjunction with the National Academy of Engineering ... learn about the impact engineers have had on our daily lives, ... been awarded "Engineering,s Nobel" since 1989. , ... Cambridge, ...
... 12 Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... and six-month periods ended December 31, 2008. Revenues for ... compared to $3.7 million for the second quarter of ... for the three months ended December 31, 2008 compared ...
Cached Biology Technology:China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 3New Educational Website Celebrates the Accomplishments of Engineers 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results 4
(Date:7/31/2014)... photovoltaic effect in 1839, humankind has sought to further ... own purposes. In a new research report published in ... Journal , scientists may have uncovered a new ... on a naturally occurring combination of lipids that have ... time and across speciessuggests that this specific natural combination ...
(Date:7/31/2014)... Hibiscus flowers- they are an iconic symbol of ... in the landscape. Some, like Hawaii,s State Flower- ... Only a relatively few botanists and Hawaiian conservation ... and intriguing related group of plants known as ... Brother of Hibiscus species are in fact highly ...
(Date:7/31/2014)... that marine noise can affect animal movement and communication, ... Bristol and Exeter and the cole Pratique des Hautes ... noise stops embryonic development and increases larval mortality in ... Stylocheilus striatus used in this study) usually ... feed on toxic alga but this study, conducted in ...
Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Brother of Hibiscus is found alive and well on Maui 2Boat noise impacts development and survival of sea hares 2
... keep a protein "watchdog" on high alert to stop hereditary ... it on a leash of just the right length. , ... University's Susan M. Mendrysa has found that one of the ... the progression of intestinal tumors that arise from genetic predisposition. ...
... one of the best-studied organisms of the open sea, ... , Understanding krill is important because they are vital ... are vulnerable to fishing pressure and environmental change. In ... of the American Institute of Biological Sciences, Stephen Nicol ...
... CONRAD and the Biosyn Division of Cellegy Pharmaceuticals, Inc. ... develop Biosyn-patented microbicides for the prevention of HIV and ... three microbicides covered under the agreement are in various ... action. They include: Savvy, which is currently in ...
Cached Biology News:Loosen leash on cancer protein 'watchdog,' researchers say 2Loosen leash on cancer protein 'watchdog,' researchers say 3Loosen leash on cancer protein 'watchdog,' researchers say 4New licensing agreement to maximize AIDS drug development 2
...
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... BD BioCoat Collagen I 60 mm Culture ... Culture Dishes, tissue-culture treated polystyrene with a uniform ... Coating : Collagen I ,Surface ... 21.3 cm2 ,Dim nominal : ...
Gelatin 100 mm Culture Dishes...
Biology Products: